Seeking Alpha
22 Sept 2026, 03:37 UTC · 1h ago
Verdict
Headline leans bullish. We score TEM +0.90 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.90strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
Q2 oncology testing volumes grew 31% YoY.
Priced inanalysis of Q2 results reported earlier
So whatConsistent double-digit volume growth supports a higher valuation multiple for FY2026.
More positive than 92% of claims this week
MRD test volumes nearly doubled since Q4 2025.
Continue reading
5 related stories
More positive than 94% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 85% of claims this week
The data & applications segment led Q2 growth at 28%.
Priced inanalysis of Q2 results reported earlier
So whatHigh-growth software revenue typically carries higher margins than testing, aiding long-term EPS.
More positive than 77% of claims this week
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
—
TEM hasn't traded since this ran. Last close $78.03 (Sep 21); the reaction starts at the next open.
TEM chart →